This is the central question in the emerging litigation
Anyone selling it as a finished injectable product right now is operating outside of approved pharmaceutical channels
Rapid weight loss can reveal underlying deficiencies
[8] [10] No room-temperature stability data for retatrutide have been published in the public domain
The individual side effect rates (nausea, vomiting, diarrhea) are similar between the two compounds, but the discontinuation rate, which reflects how many people find the side effects intolerable, is significantly lower for semaglutide (5-7%) compared to retatrutide (12-18%)
Patients in the phase 3b clinical trial maintained about 75-80% of their weight loss and health benefits, such as reduced waist circumference and improvements in blood pressure, blood sugar, triglycerides and cholesterol levels